Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2025-12-25 @ 7:06 PM
Study NCT ID:
NCT06060704
Status:
UNKNOWN
Last Update Posted:
2023-10-11
First Post:
2023-09-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-09
Completion Date Type:
ESTIMATED
First Submit Date:
2023-09-24
First Submit QC Date:
None
Study First Post Date:
2023-09-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-10-10
Last Update Post Date:
2023-10-11
Last Update Post Date Type:
ACTUAL